LRRK2 and Parkinson disease: The LRRK2 mutations impair synaptic vesicle endocytosis, leading to alterations of DA metabolism and DA-mediated toxic effects in dopaminergic neurons derived from iPSCs generated from reprogrammed PD patient fibroblasts carrying LRRK2 mutations [132].